GGrantIndex
Sort

39,280 grants matching leukemia

Molecular Mechanisms in Gastrointestinal Stromal Tumor

$573,359
Ronald P Dematteo · Sloan-Kettering Inst Can Research · R01 · FY2008 · CA

Novel Biomarkers to Risk-Stratify AML Patients with NPM1^Pos/FLT3-IT^Neg Genotype

$573,343
Derek L Stirewalt · Fred Hutchinson Cancer Research Center · R01 · FY2017 · CA

Role of T Regulatory Cells in Chronic Infection

$573,268
Ethan Shevach · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI

Protein-coding and non-coding RNA biomarkers for early detection of CLL

$573,195
George A. Calin · University Of Tx Md Anderson Can Ctr · R01 · FY2014 · CA

Activation of Proto-Oncogenes by Chromosomal Translocation

$573,096
Peter Aplan · Division Of Clinical Sciences - Nci · ZIA · FY2013 · CA

Center for Environment-Mediated Drug Resistance in Pediatric Cancer

$573,087
Yves A Declerck · Children'S Hospital Of Los Angeles · U54 · FY2012 · CA

Role of an Aberrant N6-Methyladenosine-LncRNA Axis in the Development and Maintenance of Drug Resistance through Regulating the Leukemia Stem Cell

$573,003
Shujun Liu · Case Western Reserve University · R01 · FY2024 · CA

CANCER AND LEUKEMIA GROUP B

$572,909
Brigham And Women'S Hospital · U10 · FY2000 · CA

The role for phase separation in oncogenesis and aberrant chromatin looping formation

$572,770
G Greg Wang · Duke University · R01 · FY2023 · CA

Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia

$572,741
Kara Lynn Davis · Stanford University · R01 · FY2023 · CA

Molecular Mechanisms in Gastrointestinal Stromal Tumor

$572,696
Ronald P Dematteo · Sloan-Kettering Inst Can Research · R01 · FY2007 · CA

Genetic Predictors of AML Treatment Response

$572,691
Richard Aplenc · Children'S Hosp Of Philadelphia · R01 · FY2011 · CA

NEXT GENERATION SEQUENCING ADD-ON-PHARMACOGENOMICS RESEARCH NETWROK (PGRN)

$572,671
Elaine R Mardis · Washington University · U01 · FY2012 · GM

Defining the partner interaction network of the tetraspanin CD53 in regulating B cell trafficking

$572,610
Laura G. Schuettpelz · Washington University · R01 · FY2022 · AI

OUTSTANDING INVESTIGATOR

$572,600
University Of Minnesota Twin Cities · R35 · FY2000 · CA

MOUNT SINAI COMMUNITY CLINICAL ONCOLOGY PROGRAM

$572,575
Michael Schwartz · Mount Sinai Medical Center (Miami Beach) · U10 · FY2011 · CA

MOUNT SINAI COMMUNITY CLINICAL ONCOLOGY PROGRAM

$572,572
Michael Schwartz · Mount Sinai Medical Center (Miami Beach) · U10 · FY2012 · CA

Severe Chronic Neutropenia International Registry

$572,467
David Chandler Dale · University Of Washington · R24 · FY2010 · AI

Targeting GSK3B in refractory B-cell malignancies

$572,454
Markus Mãœschen · Yale University · R01 · FY2024 · CA

RETROVIRUS EVOLUTION

$572,402
Tufts University Boston · R01 · FY2002 · CA

Gene Regulation By Steroid Receptor Proteins

$572,358
Keith Robert Yamamoto · University Of California, San Francisco · R01 · FY2013 · CA

Targeting Tumors with NF1 Loss

$572,285
Yolanda Sanchez · Dartmouth College · R01 · FY2015 · NS

Primary screening and hit follow up to identify the first selective inhibitors of PLC?1 and PLC?2

$572,254
Zhong-Yin Zhang · Purdue University · R01 · FY2025 · CA

Biomarkers for predicting response to Hsp90 therapy

$572,232
Gabriela Chiosis · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA

Screening for Resistant Enteric Bacteria to Personalize Infection Prevention Strategies in Neutropenic Patients

$572,183
Michael Joseph Satlin · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · AI